[Comment] Riluzole, disease stage and survival in ALS

Following pivotal clinical trials in amyotrophic lateral sclerosis (ALS), approval of riluzole by the US Food and Drug Administration in 1995 was met with optimism. Despite being associated with a short survival benefit of 2 –3 months equating to a 9% increase in 1-year survival,1,2 the subsequent adoption of riluzole as a treatment for ALS was perhaps reflective of a desperate need for therapeutic options in the face of this devastatingly progressive disease.3 More than two decades after riluzole was first approved f or ALS, a more efficacious treatment is yet to be discovered.
Source: Lancet Neurology - Category: Neurology Authors: Tags: Comment Source Type: research